Importantly, since the co-inhibitory checkpoint molecules expressed by both tumors and immunosuppressive cells within the TME dampens anti-tumor immunity of T cells [44,45,46,47], immune checkpoint inhibitors (ICIs) such as the antibodies directed against CTLA-4, PD-1 and PD-L1, are developed into encouraging treatments against various tumors, most notably melanoma and non-small cell lung cancer [48,49,50,51]. Here, CTLA4 is linked to melanoma.